Intravascular contrast medium is essential for enhancement of vessels and parenchyma. In this way the relation between vessels and tumours can be detected. Factors that influence the time required for a contrast bolus are the cardiac output of a patient, body weight, hydration status and the condition of the vessels. When a main vessel is occluded because of thrombosis, embolia or trauma a…
Ultrasound contrast agents (USCA) or echo enhancers consist of minute gas containing microbubbles that have a high reflectivity when exposed to an ultrasound field. The history of USCA started in the mid of the 1960s. The cardiologist Joyner performed echo cardiography during the injection of saline solution into the aortic root via a catheter. During the injection he observed bright signals on…
It has long been known that hypoxia at high altitudes leads to an increase of pulmonaryarterial pressure. For sensitive persons, one crucial factor for the development of HAPE is the overwhelming rise in pressure in the pulmonary circulation. Using right heart catheterization average pulmonary-arterial pressures of 60 mmHg were encountered in earlier studies of HAPE patients. A pressure increase…
In molecular medicine - and particularly in oncology - Siemens Medical Solutions is concentrating on further development of the FDG (fluorodeoxyglucose) biomarker to improve identification of certain tumours.
Already in 1993, the world market for contrast media was thought to be worth $ 3 billion. In 2001, an astonishing 12.2 million contrast medium-supported CT studies were carried out in Europe alone. Currently, the overall sales of contrast media are estimated to rise to $ 915 million in Europe in 2008.
Gadofosveset trisodium (trade name: Vasovist) is the first approved blood pool contrast agent worldwide for the diagnosis of vascular disease, Bayer Schering Pharma AG reports.
When the Siemens board of directors announced its decision for the new Siemens CEO on Sunday, the economic world was surprised: Not only that the name Peter Löscher was never mentioned in the previous discussions about a successor of Klaus Kleinfeld, but hardly anybody knew Loescher´s name in any enconomic context.
In 2001, an astonishing 12.2 million contrast medium-supported CT studies were carried out in Europe alone. Currently, the overall sales of contrast media are estimated to rise to $915 million in Europe in 2008.
Bracco Imaging announces that the MR Angiography indication for MultiHance has been approved by the EU member states via a mutual recognition procedure. MultiHance is a gadolinium based contrast agent that is characterized by high relaxivity and dual route of excretion.
Medtron AG is a leading European designer, manufacturer and distributor of contrast agent injectors used for CT, MRI and Angiography.
Guidelines increase the use of contrast agents.
USA - Pressure and inflammation caused by a herniated disc in the lumbar spine, and particularly painful sciatica, can be relieved using a neuroradiological technique rather than surgery, according to Dr Jeffrey A Stone, head of Interventional Neuroradiology at the Georgia Medical College, who reported on his procedure at the 44th annual meeting of the American Society of Neuroradiology in San…
Medtron AG, which designs and markets high-performance contrast agent injectors for use in CT, MRI and angiography, constantly aims to meet the demands of the latest scanner generations and advancing medical requirements, along with patient comfort and cost effectiveness.
In 1982, ulrich medical - a 3rd generation family concern based in Ulm - presented the first contrast agent injector for CT examinations.
Many procedures in diagnostic imaging would be impossible without contrast agents: they open up insights into vascular structures, show stenoses, inflammations, aneurysms and more. However, reports about side effects – especially with gadolinium-based contrast media – cause uncertainty among many patients.
